Stock Track | JACOBIO-B Plummets 12.58% Intraday After Selling JAB-23E73 License to AstraZeneca

Stock Track12-22 10:56

JACOBIO-B (01167) saw its shares plummet by 12.58% during the intraday session on Monday, following the announcement of a significant licensing deal with AstraZeneca.

The decline came after Jacobio Pharmaceuticals Group sold the worldwide license for its drug JAB-23E73 to AstraZeneca, excluding China, Hong Kong, Macau, and Taiwan. The deal includes an upfront payment of up to $100 million and potential future considerations of up to $1.92 billion, along with royalties on sales. Despite the financial benefits, investors reacted negatively, possibly due to concerns over the company's long-term strategy or revenue streams.

JAB-23E73 is a tumor medicine targeting KRAS gene alterations, and the deal involves co-development and co-commercialization in the excluded regions. The market's reaction highlights investor sensitivity to major licensing agreements and their perceived impact on future growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147008531?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-22 10:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147008531","market":"hk","top_or_hot":-1,"title":"Stock Track | JACOBIO-B Plummets 12.58% Intraday After Selling JAB-23E73 License to AstraZeneca","media":"Stock Track","content":"<p>JACOBIO-B (01167) saw its shares plummet by 12.58% during the intraday session on Monday, following the announcement of a significant licensing deal with AstraZeneca.</p><p>The decline came after Jacobio Pharmaceuticals Group sold the worldwide license for its drug JAB-23E73 to AstraZeneca, excluding China, Hong Kong, Macau, and Taiwan. The deal includes an upfront payment of up to $100 million and potential future considerations of up to $1.92 billion, along with royalties on sales. Despite the financial benefits, investors reacted negatively, possibly due to concerns over the company's long-term strategy or revenue streams.</p><p>JAB-23E73 is a tumor medicine targeting KRAS gene alterations, and the deal involves co-development and co-commercialization in the excluded regions. The market's reaction highlights investor sensitivity to major licensing agreements and their perceived impact on future growth.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | JACOBIO-B Plummets 12.58% Intraday After Selling JAB-23E73 License to AstraZeneca</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | JACOBIO-B Plummets 12.58% Intraday After Selling JAB-23E73 License to AstraZeneca\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-12-22 10:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JACOBIO-B (01167) saw its shares plummet by 12.58% during the intraday session on Monday, following the announcement of a significant licensing deal with AstraZeneca.</p><p>The decline came after Jacobio Pharmaceuticals Group sold the worldwide license for its drug JAB-23E73 to AstraZeneca, excluding China, Hong Kong, Macau, and Taiwan. The deal includes an upfront payment of up to $100 million and potential future considerations of up to $1.92 billion, along with royalties on sales. Despite the financial benefits, investors reacted negatively, possibly due to concerns over the company's long-term strategy or revenue streams.</p><p>JAB-23E73 is a tumor medicine targeting KRAS gene alterations, and the deal involves co-development and co-commercialization in the excluded regions. The market's reaction highlights investor sensitivity to major licensing agreements and their perceived impact on future growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01167","symbol_name":"加科思-B","start_time":0,"source_url":"","article_id":"1147008531","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147008531","pubTimestamp":1766372183,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"JACOBIO-B (01167) saw its shares plummet by 12.58% during the intraday session on Monday, following the announcement of a significant licensing deal with AstraZeneca.The decline came after Jacobio...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01167":"加科思-B"},"translate_title":"个股追踪|JACOBIO-B向阿斯利康出售JAB-23E73许可后盘中暴跌12.58%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01167":1},"content_text":"JACOBIO-B (01167) saw its shares plummet by 12.58% during the intraday session on Monday, following the announcement of a significant licensing deal with AstraZeneca.The decline came after Jacobio Pharmaceuticals Group sold the worldwide license for its drug JAB-23E73 to AstraZeneca, excluding China, Hong Kong, Macau, and Taiwan. The deal includes an upfront payment of up to $100 million and potential future considerations of up to $1.92 billion, along with royalties on sales. Despite the financial benefits, investors reacted negatively, possibly due to concerns over the company's long-term strategy or revenue streams.JAB-23E73 is a tumor medicine targeting KRAS gene alterations, and the deal involves co-development and co-commercialization in the excluded regions. The market's reaction highlights investor sensitivity to major licensing agreements and their perceived impact on future growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147008531","isCrawlerRequest":true}